Accuray Incorporated - Common Stock (ARAY)

Dallas TX - Sept. 28, 2026 - VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant testing technologies designed to identify unsuccessful drug candidates earlier, potentially improving the economics of pharmaceutical development.

Dallas TX - Sept. 28, 2026 - American Fusion Inc. (OTCQB: AMFN) has filed 21 additional U.S. patent applications, bringing its Texatron™ intellectual-property portfolio to 151 pending U.S. applications, as the company continues testing its fusion-energy platform and prepares for a potential national-exchange listing.

The global absorbable hydrogel tissue spacer market, used primarily in prostate cancer radiation therapy , is gaining momentum as healthcare providers increasingly adopt technologies designed to reduce treatment side effects while improving patient outcomes.

Medical technology, infection control systems, oncology radiotherapy solutions, and diagnostics innovation remain key healthcare growth themes heading into 2026—and CS Diagnostics Corp. (OTCQB: CSDX) is positioning itself at the intersection of both.

Accuray Incorporated (NASDAQ: ARAY) is one of today’s top gainers. The company’s shares are currently up 9.81% on the day to $2.85.

Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast, lung, melanoma, prostate, and colorectal cancers. Factors such as increasing incidence of metastatic cancer, rising government initiatives to spread cancer awareness, increase in healthcare expenditure, and […]